Medication info
Sitadual XR Controlled-Release Tablet 100/1000 mg (Sitagliptin Hydrochloride hydrate, Metformin Hydrochloride)

Sitadual XR Controlled-Release Tablet 100/1000 mg (Sitagliptin Hydrochloride hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hyundai Pharmaceutical Co., Ltd.
Appearance
Bright blue, bilaterally convex oval-shaped controlled-release film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300586 · Approved 2023.02.17 · Insurance code 642005010

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no history of prior antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Hyundai Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by combining the effects of sitagliptin and metformin. It supports effective management of blood sugar levels when used in conjunction with dietary and exercise regimens, thus assisting those who struggle to control their blood sugar and improving diabetes management.

How to take

Adult dose

In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no history of prior antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication contains two active ingredients, each used for the treatment of diabetes. First, this medication includes sitagliptin, which can rarely cause severe allergic reactions. Such reactions may include anaphylaxis, angioedema, and serious skin conditions. If any of these symptoms occur, discontinue the medication immediately and consult a healthcare professional. Additionally, there have been reports of a serious side effect known as acute pancreatitis, characterized by inflammation of the pancreas, so patients should notify their physician immediately if they experience symptoms of pancreatitis such as abdominal pain or vomiting during treatment. Second, the active ingredient metformin may pose risks for patients with impaired kidney function and can lead to severe metabolic abnormalities known as lactic acidosis in severe cases. Lactic acidosis can present with symptoms such as muscle pain, shortness of breath, fatigue, and abdominal pain, and immediate medical attention should be sought if these symptoms occur. This medication should not be administered to patients with severe kidney impairment, severe infections or dehydration, acute myocardial infarction, or acute heart failure. It should also not be used by women who are pregnant or breastfeeding. When taking this medication, it is important to be cautious about irregular eating habits, intense exercise, and interactions with certain medications, as hypoglycemia may occur, making it essential to check blood sugar levels frequently. Furthermore, the risk may increase when this medication is taken with alcohol, so drinking should be avoided, and the medication may need to be temporarily discontinued before and after surgery. Regular blood tests and kidney function tests should be conducted to monitor the safety of this medication, and vitamin B12 levels should also be checked periodically. Patients should be aware of potential allergies to the pigments contained in this medication, and severe joint pain or skin conditions may arise; should these symptoms occur, medical professionals should be notified immediately. Finally, in the event of an overdose of this medication, immediate medical treatment is necessary, and certain components can be removed via hemodialysis, so patients must adhere to medical guidance.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • increased liver enzymes
  • acute renal failure
  • constipation

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to protect it from air and moisture. Additionally, it is recommended to keep it at room temperature between 1°C and 30°C. This will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bright blue, bilaterally convex oval-shaped controlled-release film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.